Citadel Advisors’s Zymergen Inc. Common Stock ZY Stock Holding History

Citadel Advisors’s Portfolio ZY Stock Details ZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-71,900	Closed	-$200K	–	16029
2022 Q3	$200K	Buy	71,900 +500	+0.7%	+$1.21K	﹤0.01%	10406
2022 Q2	$88K	Sell	71,400 -14,900	-17%	-$25K	﹤0.01%	11529
2022 Q1	$249K	Sell	86,300 -41,800	-33%	-$178K	﹤0.01%	11016
2021 Q4	$857K	Buy	128,100 +8,900	+7%	+$86.4K	﹤0.01%	8335
2021 Q3	$1.57M	Buy	119,200 +111,200	+1,390%	+$2.36M	﹤0.01%	6976
2021 Q2	$320K	Buy	+8,000	New	+$316K	﹤0.01%	11115

Citadel Advisors's ZY Position: Q4 2022 in Review

Citadel Advisors sold out of Zymergen Inc. Common Stock (ZY) in Q4 2022, closing a stake of 23,345 shares — an estimated $65K sold.

Citadel Advisors first reported a position in ZY in Q2 2021 and held it in 5 quarters. The position peaked at $2.67M in Q2 2021. 0 funds tracked by Wall St. Rank hold ZY as of Q4 2022.

Citadel Advisors reported no remaining Zymergen Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 23,345 Zymergen Inc. Common Stock shares in Q4 2022, an estimated $65K.
Citadel Advisors first reported a position in Zymergen Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Citadel Advisors's Zymergen Inc. Common Stock position peaked at $2.67M in Q2 2021.
0 funds tracked by Wall St. Rank held Zymergen Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.